David H Johnson

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Xin Li, Roy S Herbst, Hai T Tran, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

Thomas J. Smith, Thomas J Smith, William Sause, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10.

Brian Findlay, Lesley Seymour, Ming-Sound Tsao, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Robert Gray, R. Gray, J. Schiller, 2006, The New England journal of medicine.

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

David M Jablons, Eric Holmgren, Roy S Herbst, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

David Harrington, D. Harrington, J. Krook, 2002, The New England journal of medicine.

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

Roy S Herbst, Vincent Miller, Rafael Rosell, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.